Antibody design relied on slow physical testing. With 12x faster AI predictions, researchers cut 1-2 wet-lab cycles per iteration.
A biotechnology startup specializing in synthetic biology and machine learning to measure and engineer protein-protein interactions for monoclonal antibody therapeutics.
Developing monoclonal antibodies requires multiple design-build-test cycles, where each iteration relies on expensive and time-consuming wet-lab...
“The stronger the binder, the higher its effectiveness as a therapeutic.”
Platform for measuring and predicting protein interactions for drug discovery.
Cloud computing platform and on-demand infrastructure services.
Provided the BioNeMo generative AI framework used by A-Alpha Bio to scale its protein predictions.
Related implementations across industries and use cases
Predicting a single protein binding took 2,000 hours. Deep learning models now complete the task in just 15 minutes.
Lab methods slowed protein analysis. An AI pipeline now scales test datasets from five items to one million in just two hours.
Matching phages required screening trillions of options. Gen AI simulates interactions, cutting discovery from 10 years to 2 months.
Silos forced teams to manually chase data. Now, AI agents identify adverse events in seconds, eliminating weeks of cross-referencing.
Attorneys juggled fragmented tools to search 50,000 cases. An AI orchestrator now routes queries to sub-agents in a single chat.
Lab supply orders were handwritten in notebooks. Digital ordering now takes seconds, saving 30,000 hours for research annually.
Experts spent 15 minutes pulling data from scattered systems. Natural language prompts now generate detailed reports instantly.